Pharmos

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Oct 26, 2020FDALotemax — EYSUVIS

Feb 22, 2019FDALotemax — LOTEMAX SM

Aug 22, 2018FDALotemax — INVELTYS

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Lotemax20 patentsMay 3, 2033 Lotemax3 patentsJan 26, 2036

Regulatory

Regulatory Timeline

19983 events

FDAMar 9

Lotemax — ALREX

Application NDA020803 (NDA)

FDAMar 9

Lotemax — LOTEMAX

Application NDA020583 (NDA)

FDAMar 9

Lotemax — LOTEMAX

Application NDA020841 (NDA)

20111 event

FDAApr 15

Lotemax — LOTEMAX

Application NDA200738 (NDA)

20121 event

FDASep 28

Lotemax — LOTEMAX

Application NDA202872 (NDA)

20181 event

FDAAug 22

Lotemax — INVELTYS

Application NDA210565 (NDA)

20191 event

FDAFeb 22

Lotemax — LOTEMAX SM

Application NDA208219 (NDA)

20201 event

FDAOct 26

Lotemax — EYSUVIS

Application NDA210933 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)